Bei Shen Pharmaceutical: a listed enterprise on the New Third Board, focusing on the inheritance and innovation of traditional Chinese medicine, and being an expert in respiratory medicine

Wuhan Bei Shen Pharmaceutical Co.
, Ltd
.
is a large-scale pharmaceutical enterprise integrating drug production, research and development, wholesale and retail, founded in 2001, as a key proprietary Chinese medicine manufacturer in Hubei Province.
The headquarters is located in Wuhan Jiangxia Jingang New District
.
In 2017, the company was listed on the New Third Board with the stock code 871910
.

Bei Shen Pharmaceutical adheres to the brand concept and unswerving quality

With the brand concept of "focusing on the inheritance and innovation of traditional Chinese medicine, and carrying forward the characteristics of traditional Chinese medicine", Bei Shen Pharmaceutical has experienced 22 years of development, and now has 14 drug approval numbers, 7 dosage form production lines, and an annual total production value of 500 million
.

The company actively responds to the national advocacy of "giving full play to the role of traditional Chinese medicine in the diagnosis and treatment of major diseases, difficult and severe diseases", strengthens the leading advantages of enterprises in the field of traditional Chinese medicine research and development, improves the research and development and production of traditional Chinese medicine varieties, and was rated as "high-tech enterprise in Hubei Province"
in 2016.

Bei Shen Pharmaceutical has strongly created a golden signboard and laid out characteristic industries

At present, the company has "Jinzhi Ai", "Amber" and other brands, with rich
product categories.
Among them, the core product "compound prince ginseng cough and qi dispersion", is a special drug for the treatment of cough and phlegm caused by qi and yin deficiency, which was successfully tested in 2015 and became an exclusive patented product in China, and has received widespread attention
from patients with its significant efficacy since its launch.
In the past 8 years, it has been confirmed in the clinical application of Wuhan Union Medical College Hospital, Hubei Provincial Hospital of Traditional Chinese Medicine, Hebei Provincial Children's Hospital, the Second Affiliated Hospital of Zhejiang Jiaxing Medical College, Xi'an Children's Hospital and other large tertiary hospitals: compound ginseng cough and qi can repair the damaged mucosa
of the respiratory tract.
This is a milestone and the cornerstone of
continuous development.

After a number of clinical studies, it has been shown that compound prince ginseng can effectively repair the damaged mucosa of the respiratory tract, enhance lung resistance, relax the bronchi, smooth breathing, effectively delay the pathogenesis cycle of slow respiratory diseases, control the recurrent attacks of cough and wheezing, bring good news to the majority of cough and phlegm and asthma patients, and let more patients share the innovative achievements
of traditional Chinese medicine.

Bei Shen Pharmaceutical keeps its mission in mind and seeks a common health cause

With the rapid development of China's economy and society and the significant improvement of people's living standards, health has become a topic
of concern for the whole society.
In the development process of Bei Shen Pharmaceutical for more than 20 years, it has always shouldered social responsibility, never forgotten its original intention, and regarded people's health as the top priority with the attitude of grasping iron marks and stepping on stones
.
From SARS to the ravages of the new crown, Bei Shen Pharmaceutical has contributed to the fight against the epidemic in an all-round and multi-level manner, opening up a broad and beautiful development prospect
for the health industry.

Since its establishment, Bei Shen Pharmaceutical has always been adhering to the business values of "serving the people with the spirit of Chinese medicine innovation", adhering to the strategic core of traditional medicine, inheriting traditional medicine culture, carrying forward the characteristics of Chinese medicine as a firm belief, carrying forward the spirit of traditional Chinese medicine to build the country and healthy human beings, building a health industry chain integrating the production, research and marketing of traditional Chinese medicine with famous doctors, famous drugs and the people, committed to promoting the development of traditional Chinese medicine, being a health messenger to improve the quality of life of the people, and becoming a responsible and responsible Excellent Chinese medicine enterprise
with responsibility.

Between breathing tension, the future is still promising

Intensive cultivation of market segments, continuous development and innovation
.
In recent years, with the sweep of the Internet wave, the company has built an online Chinese medicine sales platform and opened up a new layout
for the development of the promotion and application of green therapy in Chinese medicine.
At the same time, in 2021, it will be certified as "Hubei Province Specialized and Special New Little Giant Enterprise", and in 2022, it will be awarded the title of provincial "Specialized and Special New Enterprise", and determine the strategy of large varieties of traditional Chinese medicine advantages of the enterprise, and carry out precision treatment
of traditional Chinese medicine.

As a listed enterprise on the New Third Board, Bei Shen Pharmaceutical Group will continue to uphold the brand concept on the future development path, resonate with the national pharmaceutical policy and strategic layout at the same frequency, assume the responsibility of private enterprises in the new era, regard people's respiratory health as the mission, breath and relax, exhale outward, grow inward, and the development of the enterprise and the take-off of the private economy go hand in hand and continue to advance
.